Regeneron Pharmaceuticals Inc (REGN)

[crudeoil24]

After Recent Disappointments, Ocular Thera Pleases -- Market Talk
45 minutes ago - DJNF
7:49 ET - Ocular Therapeutix (OCUL) ended yesterday's trading with a $157M market cap. Regeneron (REGN) has entered a deal with the biopharma to potentially pay OCUL nearly twice that in milestone payments as part of a retinal-disease collaboration. Bigger drugmakers have made dozens of such deals with developers in recent years as to not depend just on their own pipeline but potential novel treatments created by others. In a number of cases, such agreements have ended up being the first step to a buyout. OCUL is up 23% premarket at $7.77 after having slid 8.2% this month and trading at just half of early-June levels. Then, it released more disappointing clinical data. ([e-mail]; @kevinkingsbury)